Medicines Safety in Dementia Care: Practical Systems That Prevent Harm and Stand Up to Scrutiny
Medicines safety in dementia care depends on reliable systems and consistent staff practice, not individual heroics. People living with dementia may refuse, forget, double-dose, become distressed during prompts, or experience side effects that look like “behaviour” or deterioration. These risks sit alongside frailty, falls risk and multi-morbidity. This article supports the Medicines, Frailty, Falls & Safety focus area and should be read alongside wider delivery approaches within dementia service models used in UK adult social care.
Why medicines risk is different in dementia care
Medicines processes can fail quietly in dementia services because the person may not be able to report symptoms or describe what has happened. “Normal” administration prompts can also trigger distress, especially when language is complex or staff are rushed. Common dementia-specific risks include:
- Refusal or covert non-adherence (spitting out, hiding tablets, repeated “no”)
- Duplicate dosing (staff changeovers, agency staff, unclear records)
- PRN drift (PRN becoming routine without review or clear rationale)
- Side effects misread as deterioration (sedation, postural hypotension, delirium)
- Safeguarding risks where medicines are administered without valid consent pathways
High-quality services treat medicines management as a core clinical-safety system with governance, audit trails and clear escalation routes.
Commissioner expectation: medicines governance that evidences risk control
Commissioner expectation: services should demonstrate robust medicines governance: accurate records, trained staff, safe storage, clear accountability, timely GP/pharmacy liaison, and evidence that risks are identified, reviewed and reduced (not just recorded). Commissioners also expect visible learning from incidents and near-misses.
Regulator expectation (CQC): safe administration, consent and learning
Regulator / Inspector expectation (CQC): inspectors will look for safe processes, competent staff, and the ability to explain how medicines decisions are made and reviewed. CQC lines of enquiry often test whether PRN is used appropriately, whether refusals are managed safely and lawfully, and whether the service learns from errors and patterns.
Core operational controls that prevent medicines harm
1) Clear roles, competencies and shift discipline
Medicines administration should be assigned to competent staff with formal sign-off, not “whoever is free”. Operational controls typically include:
- named medicines lead (Registered Manager or delegated senior) with oversight responsibilities
- competency-based assessment for administration, including dementia-specific scenarios (refusal, distress, covert administration)
- protected time for rounds to reduce rushing and interruptions
- handover checks that explicitly confirm outstanding doses, refusals and PRN usage
2) Record integrity: MAR, omissions and rationale
Strong services expect MAR charts to tell a complete story, including omissions and the reasons. “Not given” is not enough. Records should show what was offered, the person’s response, what de-escalation was used, and what escalation occurred (if required). This matters in dementia care because repeated omissions may signal distress triggers, swallowing issues, pain, delirium or side effects.
3) PRN governance: thresholds, review and de-prescribing conversations
PRN medicines require tight governance in dementia services because they can become a proxy for staffing pressure. A practical PRN framework includes:
- clear indication (what it is for, not just the drug name)
- non-pharmacological steps first (what staff must try before PRN)
- minimum interval rules and maximum daily dose rules understood by staff
- review triggers (e.g. PRN used more than X times in Y days prompts GP review)
- monthly PRN audit by a senior, with themes reported
Operational example 1: refusal pathway reduces risk and distress
Context: A person living with dementia began refusing morning medicines. Staff were repeatedly returning, offering multiple times, and documenting “refused” without escalation. Incidents of agitation increased, and medicines omissions became frequent.
Support approach: The service implemented a structured refusal pathway: identify triggers, reduce cognitive demand, offer choices (time and method), and escalate clinically when refusal persists. The person’s care plan was updated with dementia-friendly prompts and consent-consistent practice.
Day-to-day delivery detail: Staff used short prompts, a calm approach, and offered medicines with preferred drink and at a quieter time. Staff stopped repeated prompting once refusal was clear, recorded the rationale, and informed the shift lead. The lead reviewed omissions daily and contacted GP/pharmacy if refusal repeated beyond an agreed threshold.
How effectiveness is evidenced: MAR audits showed fewer omissions. Incident logs reduced. Notes demonstrated consistent approach across staff teams. A GP review identified swallowing discomfort and timing issues, leading to formulation changes and improved adherence.
Operational example 2: PRN drift detected and corrected through audit
Context: PRN anxiolytic medication was being used most evenings for one person, but records described “restless” without detail. Staff believed PRN was the normal response.
Support approach: The medicines lead introduced PRN governance: behaviour mapping, required documentation of non-pharmacological steps, and GP review triggers.
Day-to-day delivery detail: Staff were coached to record what they observed (pace, triggers, environment) and to try specific de-escalation steps first (walk, low-stimulation space, reassurance, meaningful task). PRN could only be given when clear thresholds were met and documented. Weekly review in handover identified patterns.
How effectiveness is evidenced: PRN usage reduced. Behaviour mapping showed distress correlated with noise at shift-change; environmental changes reduced agitation. GP review agreed a de-prescribing plan and alternative supports. Audit trails demonstrated learning and oversight.
Operational example 3: medicines side effects identified as a falls driver
Context: A person experienced repeated near-falls and one fall with no clear environmental cause. Staff initially focused on mobility and footwear.
Support approach: The service linked falls review with medicines review, recognising that postural hypotension and sedation can present as unsteadiness and confusion in dementia care.
Day-to-day delivery detail: Staff introduced postural blood pressure checks (as agreed with clinical partners), recorded “time of day” correlation with dosing, and ensured hydration prompts. The service liaised with GP regarding medication timing and potential side effects. Night-time checks were adjusted to avoid unnecessary waking that increased disorientation.
How effectiveness is evidenced: Falls and near-falls reduced after medicines adjustments. The falls log showed fewer incidents at previously high-risk times. Review documentation demonstrated integrated learning across medicines and falls governance.
Safeguarding, consent and covert administration
In dementia care, medicines administration must remain legally and ethically sound. If a person lacks capacity for a specific medicines decision, the service should evidence decision-making under the Mental Capacity Act, involving the right people and documenting best interests. Covert administration must never be a “quiet workaround”; it requires a formal, documented process with clinical oversight and clear review points. Poor practice here becomes a safeguarding concern quickly.
Governance and assurance: what “audit-ready” looks like
Services that stand up to scrutiny usually have a visible medicines governance rhythm:
- weekly MAR spot checks and monthly full MAR audits with themes logged
- PRN monitoring reports and review triggers
- training and competency records with refresher cycles
- incident and near-miss reviews with actions tracked to completion
- evidence of liaison with pharmacy/GP and implementation of recommendations
The goal is not paperwork — it is consistent practice, risk reduction, and a clear evidence trail of learning and improvement.
Practical takeaway
Medicines safety in dementia care is achieved through structured refusal pathways, PRN governance, record integrity and strong escalation. When those controls are embedded into day-to-day routines and evidenced through audits and reviews, services reduce harm and demonstrate commissioner- and CQC-aligned quality.